Difference between revisions of "Profiles"

From QIBA Wiki
Jump to: navigation, search
m
m (Stage 1: Public Comment Profiles)
 
(51 intermediate revisions by 3 users not shown)
Line 18: Line 18:
 
===[[QIBA_Profile_Stages#Stage_2:_Consensus|Stage 2]]: Consensus Profiles===
 
===[[QIBA_Profile_Stages#Stage_2:_Consensus|Stage 2]]: Consensus Profiles===
  
* [[Media:QIBA_DWIProfile_Consensus_Dec2019_Final.pdf|Diffusion-Weighted Magnetic Resonance Imaging (DWI) 2019-12-20]]
+
*[[Media:QIBA_CT_Lung_Density_Profile_090420-clean.pdf | QIBA CT Lung Density Profile_09.04.2020, clean version]] (Contains Conformance Checklist, Appendix B) 2020-10-23
 +
:*[[Media:QIBA CT Lung Density Protocols-Appendix E.xlsx|Appendix E:CT Lung Density Protocols 2019-06-26]]  
  
*[[Media:QIBA_AmyloidPET_20June2018_consensus.pdf | 18F-labeled PET tracers targeting Amyloid as an Imaging Biomarker 2018-06-20]]  
+
*[[Media:QIBA_DSC-MRI_Stage2-Consensus_Profile.pdf| MR Dynamic Contrast Susceptibility (DSC) 2020-10-22]]
  
*[[Media:MRE-QIBA_Profile-2019-06-06-CONSENSUS-maintenance.pdf | MR Elastography of the Liver 2019-06-06]]  
+
*[[Media:QIBA_DWIProfile_Consensus_Dec2019_Final.pdf| MR Diffusion-Weighted Imaging (DWI) 2019-12-20]]
  
*[[Media:001.QIBA_SPECT_Ioflupane Profile.v1.1 post-public comments.clean copy.2017 06 26.pdf | SPECT Quantifying Dopamine Transporters with 123 - Iodine Labeled Ioflupane in Neurodegenerative Disease v1.1, 2017-06-26]]
+
*[[Media:QIBA_AmyloidPET_20June2018_consensus.pdf | PET F-18 for Amyloid 2018-06-20]]  
  
*[[Media:002.QIBA SPECT Ioflupane Profile v2.0.2019 10 15.pdf | SPECT Quantifying Dopamine Transporters with 123 - Iodine Labeled Ioflupane in Neurodegenerative Disease v2.0, 2019-10-15]]
+
*[[Media:MRE-QIBAProfile-2018-05-02-CONSENSUS.pdf | MR Elastography of the Liver 2018-05-02]]
 +
 
 +
*[[Media:001.QIBA_SPECT_Ioflupane Profile.v1.1 post-public comments.clean copy.2017 06 26.pdf | SPECT Ioflupane for Neurodegenerative Disease v1.1, 2017-06-26]]
 +
 
 +
*[[Media:002.QIBA SPECT Ioflupane Profile v2.0.2019 10 15.pdf | SPECT Ioflupane for Neurodegenerative Disease v2.0, 2019-10-15]]
  
 
:*[[Media:002.QIBA SPECT Profile Checklist Extract.2016 10 31.docx|Checklist - SPECT Profile Conformance]]
 
:*[[Media:002.QIBA SPECT Profile Checklist Extract.2016 10 31.docx|Checklist - SPECT Profile Conformance]]
Line 32: Line 37:
 
*[[Media:DCE-MRI Quantification Profile v1.0.pdf|MR DCE Quantification v1.0 2012-08-08]]
 
*[[Media:DCE-MRI Quantification Profile v1.0.pdf|MR DCE Quantification v1.0 2012-08-08]]
  
 +
*[[Media:QIBA_CTA_Profile_as_of_2020-Mar-10.pdf| CTA Atherosclerosis 2020-03-10]]
 +
:*[[Media:QIBA_CTA_Field Test Checklist.xlsx| CTA Atherosclerosis Checklist 2020-05-28]]
  
===[[QIBA_Profile_Stages#Stage_1:_Public_Comment|Stage 1]]: Public Comment Profiles===
+
*[[Media:QIBA_SPECT_99mTC_Profile_10.21.19.pdf|SPECT-CT: Estimating the Concentration of 99mTc Based Imaging Biomarkers in Large and Small Volumes of Interest Profile 2019-10-21]]
  
'''Please submit comments using the '''[http://tinyurl.com/QIBA-Public-Comment-Form '''online form''']'''
 
  
*[[Media:QIBA_DSC-MRI_Stage1_Profile.pdf|Dynamic Susceptibility Contrast MRI (DSC-MRI) Profile 2020-01-29]] (<font color=green>'''Public Comment Open''': March 2 - May 15, 2020<font>)
+
===[[QIBA_Profile_Stages#Stage_1:_Public_Comment|Stage 1]]: Public Comment Profiles===
  
*[[Media:QIBA_SPECT_99mTC_Profile_10.21.19.pdf|SPECT-CT: Estimating the Concentration of 99mTc Based Imaging Biomarkers in Large and Small Volumes of Interest Profile 2019-10-21]] (<font color=#8b0000>'''closed''' on February 3, 2020<font>)
+
'''Please submit comments using the '''[https://forms.gle/bPzUAuLKJnHYGbVS7 '''online form''']'''
  
*[[Media:QIBA_US_SWS_Profile_10.21.19.pdf|QIBA US Measurement of Shear Wave Speed for Estimation of Liver Fibrosis Profile 2019-10-21]] ('''closed''' on December 18, 2019)
+
*[[Media:QIBA_DCE-MRI_Profile-Stage_1-Public_Comment.pdf|MR DCE-MRI Quantification (DCEMRI-Q) 2020-10-12]] ('''closed''' on March 10, 2021)
  
:*[[Media:SWS Checklists-Appendix E.xlsx|Appendix E: QIBA US SWS Checklists for Implementation of the SWS Profile, 2019-10-21]] ('''closed''' on December 18, 2019)
+
*[[Media:QIBA_Profile_MSK-Cartilage-Stage1_Profile.pdf|MR MSK cartilage for joint disease 2020-05-18]] ('''closed''' on October 29, 2020)
  
*[[Media:QIBA_CT_Lung_Density_Profile_090319-clean.pdf | QIBA CT Lung Density Profile 2019-09-03]] (Contains Conformance Checklist, Appendix B) ('''closed''' on October 16, 2019)
+
*[[Media:QIBA_US_SWS_Profile_10.21.19.pdf|US Shear Wave Speed for Liver Fibrosis 2019-10-21]] ('''closed''' on December 18, 2019)
  
:*[[Media:QIBA CT Lung Density Protocols-Appendix E.xlsx|QIBA CT Lung Density Protocols-Appendix E, 2019-06-26]] ('''closed''' on October 16, 2019)
+
:*[[Media:SWS Checklists-Appendix E.xlsx|Appendix E: SWS Checklists, 2019-10-21]] ('''closed''' on December 18, 2019)
  
*[[Media:QIBA_CTA_Profile_as_of_2019-Feb-29.pdf| Atherosclerosis Biomarkers by (C)CTA - 2019 Imaging Profile 2019-02-26]] ('''closed''' on June 3rd, 2019)
+
*[[Media:QIBA_fMRI_Profile_1_PC-rev1.pdf| fMRI for Sensorimotor Mapping 2017-06-19]] ('''closed''' on December 31, 2017)
  
  
 
'''[[Comment Resolutions]]''' <font color=black>are posted for '''Past Public Comments''' and '''Past Technical Confirmations'''.<font>
 
'''[[Comment Resolutions]]''' <font color=black>are posted for '''Past Public Comments''' and '''Past Technical Confirmations'''.<font>
  
==Format for Citing Profiles==
+
 
 +
====Format for Citing Profiles====
 
Cite QIBA Profile documents as:
 
Cite QIBA Profile documents as:
  
: ''Specific QIBA Biomarker Committee. Specific Profile Title'', Quantitative Imaging Biomarkers Alliance. ''Version. Profile Stage''. QIBA, ''Date''. Available from: ''URL''
+
: ''Specific QIBA Biomarker Committee. Specific Profile Title'', Quantitative Imaging Biomarkers Alliance. ''Version. Profile Stage''. ''Date''. Available from: ''URL''
  
 
Example:
 
Example:
  
: QIBA SPECT Biomarker Committee. Quantifying Dopamine Transporters with 123Iodine Labeled Ioflupane in Neurodegenerative Diseases, Quantitative Imaging Biomarkers Alliance. Version 1.1.  Profile Stage: Consensus. QIBA, June 30, 2017. Available from: http://qibawiki.rsna.org/index.php/Profiles
+
: QIBA MR Biomarker Committee. MR Elastography of the Liver, Quantitative Imaging Biomarkers Alliance. Profile Stage: Consensus. June 6, 2019. Available from: http://qibawiki.rsna.org/index.php/Profiles
  
  
==Statements of Endorsement==
+
====Statements of Endorsement====
 
*[[Industry]]
 
*[[Industry]]
 
*[[Clinical Sites]]
 
*[[Clinical Sites]]
Line 70: Line 77:
  
  
==See Also==
+
====See Also====
 
*[[How to use QIBA Profiles]]
 
*[[How to use QIBA Profiles]]
 
*[[Committees|Biomarker Committee]] pages may also have links to DRAFT Profile documents for the next Stage.
 
*[[Committees|Biomarker Committee]] pages may also have links to DRAFT Profile documents for the next Stage.

Latest revision as of 23:47, 12 May 2021

Profiles published here have completed one of the QIBA Profile Stages of development and been approved by their Biomarker Committee.

Profiles may be of use at any Stage.

Stage 3: Technically Confirmed Profiles

  • Conformance Checklists (refer to Appendix C in the Profile document - pg 42)
  • Assessment Procedures (refer to Section 4 in the Profile document - pg 30)


Stage 2: Consensus Profiles


Stage 1: Public Comment Profiles

Please submit comments using the online form


Comment Resolutions are posted for Past Public Comments and Past Technical Confirmations.


Format for Citing Profiles

Cite QIBA Profile documents as:

Specific QIBA Biomarker Committee. Specific Profile Title, Quantitative Imaging Biomarkers Alliance. Version. Profile Stage. Date. Available from: URL

Example:

QIBA MR Biomarker Committee. MR Elastography of the Liver, Quantitative Imaging Biomarkers Alliance. Profile Stage: Consensus. June 6, 2019. Available from: http://qibawiki.rsna.org/index.php/Profiles


Statements of Endorsement


See Also